Board Meeting Outcome for Consideration and Approval of Standalone & Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March, 2026, along with Auditor's ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Parnax Lab Ltd reported mixed FY26 results with consolidated revenue growing 32.4% to Rs 2,485.44 Cr from Rs 1,877.38 Cr, while standalone revenue declined 5.6% to Rs 66.25 Cr from Rs 70.19 Cr. Consolidated PAT grew modest 2.2% to Rs 117.99 Cr vs Rs 115.39 Cr, but standalone PAT fell sharply by 36.3% to Rs 8.88 Cr from Rs 13.95 Cr. The auditors issued an unmodified (clean) opinion on both standalone and consolidated results. Exceptional items of Rs 3.49 lakh (standalone) and Rs 136.93 lakh (consolidated) were recognised due to new labour code impact. Standalone operating cash flow turned negative at Rs -72.05 lakh vs positive Rs 27.91 lakh in prior year. The Board also re-appointed Mr. Yogesh K. Varia as Independent Director for a second 5-year term.
Consolidated revenue growth is strong but profit growth is muted; standalone operations are deteriorating with PAT declining 36% and negative operating cashflow. The company appears dependent on its subsidiary (Naxpar Pharma Private Limited) which contributed Rs 1,091.11 Cr revenue to the group.